Cited by 375Lymphoma Diagnosis and TreatmentNF-κB Signaling PathwaysViral-associated cancers and disorders

Aberrantly expressed c‐Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF‐κB

Open access
Mathas, Stephan, Hinz, Michael, Anagnostopoulos, Ioannis, Krappmann, Daniel, Lietz, Andreas, Jundt, Franziska, Bommert, Kurt, Mechta‐Grigoriou, Fatima +3 more·2002·The EMBO Journal

Abstract

AP-1 family transcription factors have been implicated in the control of proliferation, apoptosis and malignant transformation. However, their role in oncogenesis is unclear and no recurrent alterations of AP-1 activities have been described in human cancers. Here, we show that constitutively activated AP-1 with robust c-Jun and JunB overexpression is found in all tumor cells of patients with classical Hodgkin's disease. A similar AP-1 activation is present in anaplastic large cell lymphoma (ALCL), but is absent in other lymphoma types. Whereas c-Jun is up-regulated by an autoregulatory process, JunB is under control of NF-kappa B. Activated AP-1 supports proliferation of Hodgkin cells, while it suppresses apoptosis of ALCL cells. Furthermore, AP-1 cooperates with NF-kappa B and stimulates expression of the cell-cycle regulator cyclin D2, proto-oncogene c-met and the lymphocyte homing receptor CCR7, which are all strongly expressed in primary HRS cells. Together, these data suggest an important role of AP-1 in lymphoma pathogenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/emboj/cdf389

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Different studies in several human neoplasms, including CRC, showed higher c-JUN expression and activation in tumors compared to normal tissue.

    “Different studies in several human neoplasms [50–53], including CRC [54], showed higher c-JUN expression and activation in tumors compared to normal tissue.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mathas, S., Hinz, M., Anagnostopoulos, I., Krappmann, D., Lietz, A., Jundt, F., Bommert, K., Mechta‐Grigoriou, F., Stein, H., Dörken, B., & Scheidereit, C.
Affiliations
  • Max Delbrück Center (DE)
  • Freie Universität Berlin (DE)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Scheidereit, Claus
Venue
The EMBO Journal
Published
2002-08-01
Volume
21
Issue
15
Pages
4104-4113
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W2098180441
Cited by
375
References
47
Citations by year
2026: 6 · 2025: 10 · 2024: 7 · 2023: 26 · 2022: 7 · 2021: 13 · 2020: 10 · 2019: 10 · 2018: 16 · 2017: 12 · 2016: 19 · 2015: 21 · 2014: 16 · 2013: 13 · 2012: 14
FWCI
15.07
Type
journal article
Language
en
Open access
Locations
  • The EMBO Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
c-Jun, JunB, AP-1 transcription factor, Hodgkin's disease, anaplastic large cell lymphoma, NF-κB, cell proliferation, apoptosis, cyclin D2, c-Met, CCR7, lymphomagenesis, autoregulation
MeSH terms
Proto-Oncogene Mas, Cell Division, Cell Transformation, Neoplastic, DNA, Neoplasm, Hodgkin Disease, Humans, Lymphoma, Non-Hodgkin, Mitogens, Neoplasm Proteins, Recombinant Fusion Proteins, Tetradecanoylphorbol Acetate, Transcription, Genetic, Transfection, Tumor Cells, Cultured, Ultraviolet Rays, Gene Expression Regulation, Neoplastic, Cyclins, NF-kappa B, Lymphoma, Large B-Cell, Diffuse, Reed-Sternberg Cells, Proto-Oncogene Proteins c-jun, Genes, jun, Transcription Factor AP-1, Receptors, Chemokine, Proto-Oncogene Proteins c-met, MAP Kinase Signaling System, Receptors, CCR7, Cyclin D2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review